<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>First- and second-line agents used in the treatment of adults with alcohol use disorder</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">First- and second-line agents used in the treatment of adults with alcohol use disorder</h1>
<div class="graphic"><div class="figure"><div class="ttl">First- and second-line agents used in the treatment of adults with alcohol use disorder</div><div class="cntnt"><table cellspacing="0"><colgroup span="6" width="16%"></colgroup> <tbody> <tr> <td class="subtitle1"> </td> <td class="subtitle1">Initial daily dose</td> <td class="subtitle1">Titration or daily dose range</td> <td class="subtitle1">Select adverse effects*</td> <td class="subtitle1">Contraindications</td> <td class="subtitle1">Dosing and monitoring considerations</td> </tr> <tr class="highlight_lght_gray_text"> <td colspan="6"><strong class="heading">First-line agents:</strong> For newly diagnosed patients with moderate to severe alcohol use disorder, we prefer naltrexone. In individuals who are prescribed opioids or are using opioids or in those with hepatic failure or acute hepatitis, we use acamprosate.</td> </tr> <tr> <td class="indent1">Naltrexone (intramuscular)</td> <td>380 mg IM every 4 weeks.</td> <td class="centered">—</td> <td> <p><strong>Injection site reaction:</strong> pain, cellulitis, hematoma, induration, sterile abscess.</p> <p><strong>Neurologic:</strong> headache, dizziness, sleep disturbance.</p> <p><strong>Gastrointestinal:</strong> nausea, decreased appetite, abdominal pain.</p> <strong>Hepatic:</strong> increased transaminases.</td> <td rowspan="2"> <p>Hypersensitivity to naltrexone or component of formulation.</p> <p>Current opioid use or prescription for pain management.</p> Hepatic failure or elevated liver enzymes ≥3 to 5 times normal.</td> <td rowspan="2"> <p>May begin treatment while patient is still drinking.</p> Liver enzymes should be monitored within several weeks of initiating treatment and then every 6 months during ongoing treatment.</td> </tr> <tr> <td class="indent1">Naltrexone (oral)</td> <td>50 mg orally once daily. Some individuals may require titration to 100 mg once daily after 1 week.</td> <td>Usual dosage range: 50 to 100 mg/day.</td> <td> <p><strong>Neurologic:</strong> headache, dizziness, sleep disturbance.</p> <p><strong>Gastrointestinal:</strong> nausea, decreased appetite, abdominal pain.</p> <strong>Hepatic:</strong> increased transaminases.</td> </tr> <tr> <td class="indent1">Acamprosate</td> <td>666 mg orally 3 times daily.</td> <td class="centered">—</td> <td> <p><strong>Gastrointestinal:</strong> diarrhea.</p> <strong>Neurologic:</strong> anxiety, insomnia, depression, dizziness.</td> <td> <p>Hypersensitivity to acamprosate.</p> CrCl &lt;30 mL/min.</td> <td> <p>Lower initial dose (ie, 333 mg orally 3 times daily) recommended for individuals with moderate kidney impairment (CrCl 30 to 50 mL/min).</p> Lower initial dose (ie, 333 mg 2 times daily) recommended for individuals weighing &lt;60 kg.</td> </tr> <tr class="highlight_lght_gray_text"> <td colspan="6"><strong class="heading">Second-line agents:</strong> In individuals who have not had clinically acceptable response to initial agents, we suggest the following agents. In individuals with seizure disorder, we use topiramate.</td> </tr> <tr> <td class="indent1">Disulfiram</td> <td>Loading dose: 250 to 500 mg orally once daily for 1 to 2 weeks.</td> <td>After loading dose, average maintenance dose is 250 mg orally once daily (range: 125 to 500 mg/day).</td> <td> <p><strong>Neurologic:</strong> fatigue, headache, bitter (garlic) taste, neuropathy.</p> <strong>Hepatic:</strong> hepatitis.</td> <td>Severe myocardial disease, psychosis, hypersensitivity to thiuram derivatives, ongoing alcohol use.</td> <td>Liver enzymes should be monitored within several weeks of initiating treatment and then every 6 months during ongoing treatment.</td> </tr> <tr> <td class="indent1">Topiramate (immediate release)</td> <td>25 mg orally once daily.</td> <td>Increase daily dose by 25 mg per week for 4 weeks, then increase by 50 mg per week to maximum dose of 300 mg per day as tolerated. Daily doses &gt;50 mg are administered in divided <span class="nowrap_whitespace">doses.<sup>¶</sup></span></td> <td> <p><strong>Gastrointestinal:</strong> abdominal pain, diarrhea, nausea.</p> <p><strong>Metabolic:</strong> weight loss.</p> <strong>Neurologic:</strong> dizziness, drowsiness, fatigue, cognitive impairment (eg, memory impairment, word finding difficulties), paresthesias.</td> <td>Hypersensitivity to topiramate.</td> <td>Lower doses (eg, 50% dose reduction) and slower titration recommended for kidney impairment (CrCl &lt;70 mL/min/<span class="nowrap_whitespace">1.73 m<sup>2</sup>).</span></td> </tr> <tr> <td class="indent1">Gabapentin</td> <td>300 mg orally once daily.</td> <td>Increase daily dose by 300 mg every 1 to 2 days as tolerated to target dose of 600 mg 3 times daily.</td> <td> <p><strong>Neurologic:</strong> dizziness, drowsiness, mood changes.</p> <p><strong>Gastrointestinal:</strong> nausea, diarrhea.</p> Risk for misuse and addiction.</td> <td>Hypersensitivity to gabapentin or components of formulation.</td> <td>Lower doses recommended for kidney impairment (CrCl &lt;50 mL/min).</td> </tr> </tbody></table></div><div class="graphic_lgnd">In patients with a robust response to therapy or in remission, UpToDate prefers continuation of pharmacotherapy and psychosocial supports for one year or more. In patients who are not meeting treatment goals, we regularly reassess treatment plan and will typically intensify psychosocial supports and consider dose adjustment, if applicable. If adequate progress is not demonstrated within 6 months of initiating a first- or second-line agent, we consider alternative pharmacotherapy. Refer to UpToDate topic reviews of approach to treating alcohol use disorder for additional guidance.</div><div class="graphic_footnotes"><p>IM: intramuscularly; CrCl: creatinine clearance.</p>
<p>* This is not a complete list. For more information, refer to Lexicomp drug information included with UpToDate.</p>
¶ Refer to topiramate dose-escalation table in UpToDate.</div><div id="graphicVersion">Graphic 131714 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
